|
|
||||||||
From the Department of Obstetrics and Gynecology (E. Kaaja and Drs. R. Kaaja and Hiilesmaa), Helsinki University Central Hospital; and Division of Pharmacology and Toxicology (E. Kaaja), Department of Pharmacy, University of Helsinki, Finland.
Address correspondence and reprint requests to Dr. Vilho Hiilesmaa, Department of Obstetrics and Gynecology, Helsinki University Central Hospital, P.O. Box 140, 00029 HUCH, Finland; e-mail: ville.hiilesmaa{at}hus.fi
Background: The offspring of women with epilepsy are at an increased risk of major congenital malformations, but the impact of the various contributing factors remains unresolved.
Method: In 1980 through 1998, the authors prospectively followed up 970 pregnancies in women with epilepsy at a single maternity clinic. Of their 979 offspring, 740 were exposed to maternal antiepileptic drugs (AED) during the first trimester of pregnancy and 239 were not exposed. Maternal AED levels and serum folate concentrations were measured at the end of the first trimester. Logistic regression analysis was applied to identify factors associated with the occurrence of major malformations in the fetuses and newborns.
Results: Major malformations were detected in 28 fetuses (3.8%) exposed to maternal AED and in 2 (0.8%) not exposed (p = 0.02). After logistic regression analysis, the occurrence of major malformations was independently associated with use of carbamazepine (adjusted OR 2.5; 95% CI 1.0 to 6.0), use of valproate (4.1; 1.6 to 11), use of oxcarbazepine (10.8; 1.1 to 106), low serum folate concentration (5.8; 1.3 to 27), and low maternal level of education (3.0; 1.3 to 6.8). Major malformations were not associated with seizures during the first trimester (0.6; 0.1 to 2.9).
Conclusions: Major malformations in the offspring of mothers with epilepsy are associated with use of AED during early pregnancy, and also with low serum folate concentrations and a low level of education.
This article has been cited by other articles:
![]() |
T. Tomson and V. Hiilesmaa Epilepsy in pregnancy BMJ, October 13, 2007; 335(7623): 769 - 773. [Full Text] [PDF] |
||||
![]() |
M. Artama, J.I.T. Isojarvi, and A. Auvinen Antiepileptic drug use and birth rate in patients with epilepsy--a population-based cohort study in Finland Hum. Reprod., September 1, 2006; 21(9): 2290 - 2295. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. J. Meador, G. A. Baker, R. H. Finnell, L. A. Kalayjian, J. D. Liporace, D. W. Loring, G. Mawer, P. B. Pennell, J. C. Smith, M. C. Wolff, et al. In utero antiepileptic drug exposure: Fetal death and malformations Neurology, August 8, 2006; 67(3): 407 - 412. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Jackson Epilepsy in women: a practical guide to management Practical Neurology, June 1, 2006; 6(3): 166 - 179. [Full Text] [PDF] |
||||
![]() |
R. D. Sheth and B. E. Gidal Topical Review: Optimizing Epilepsy Management in Teenagers J Child Neurol, April 1, 2006; 21(4): 273 - 279. [Abstract] [PDF] |
||||
![]() |
M. Artama, A. Auvinen, T. Raudaskoski, I. Isojarvi, and J. Isojarvi Antiepileptic drug use of women with epilepsy and congenital malformations in offspring Neurology, June 14, 2005; 64(11): 1874 - 1878. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Penovich and E. Gaily What can we say to women of reproductive age with epilepsy? Neurology, March 22, 2005; 64(6): 938 - 939. [Full Text] [PDF] |
||||
![]() |
M. Cunnington, P. Tennis, and the International Lamotrigine Pregnancy Registry S Lamotrigine and the risk of malformations in pregnancy Neurology, March 22, 2005; 64(6): 955 - 960. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. F. Wyszynski, M. Nambisan, T. Surve, R. M. Alsdorf, C. R. Smith, L. B. Holmes, and for the Antiepileptic Drug Pregnancy Registry Increased rate of major malformations in offspring exposed to valproate during pregnancy Neurology, March 22, 2005; 64(6): 961 - 965. [Abstract] [Full Text] [PDF] |
||||
![]() |
Antiepileptics, pregnancy and the child DTB, February 1, 2005; 43(2): 13 - 16. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. Perucca NICE guidance on newer drugs for epilepsy in adults BMJ, May 29, 2004; 328(7451): 1273 - 1274. [Full Text] [PDF] |
||||
![]() |
E. Gaily, E. Kantola-Sorsa, V. Hiilesmaa, M. Isoaho, R. Matila, M. Kotila, T. Nylund, A. Bardy, E. Kaaja, and M. -L. Granstrom Normal intelligence in children with prenatal exposure to carbamazepine Neurology, January 13, 2004; 62(1): 28 - 32. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Miller, J. D'Souza, R. Zaninelli, R. Meischenguiser, C. H. D'Giano, S. M. Ferraro, E. Kaaja, R. Kaaja, and V. Hiilesmaa Major malformations in offspring of women with epilepsy Neurology, December 9, 2003; 61(11): 1631 - 1632. [Full Text] [PDF] |
||||
![]() |
Fetal Malformations and Antiepileptic Medications Journal Watch Psychiatry, April 9, 2003; 2003(409): 5 - 5. [Full Text] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |